Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.
1 report, 1 independent
Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
-
Securities and Exchange Commission
government agency of the Philippines
Related events
- Cantor Fitzgerald raised its price target on Salesforce on September 1, 2026.
- Cantor Fitzgerald raised its price target and rating, while Bank of America adjusted its rating and price target, with MarketBeat aggregating the stock rating data.
- Cantor Fitzgerald and Wells Fargo raised price targets for Regeneron Pharmaceuticals stock.
- Cantor Fitzgerald, Morgan Stanley, and Royal Bank of Canada issued price target updates for Elevance Health, Inc. on September 12, 2026.
- Cantor Fitzgerald raised its price target on Texas Instruments shares on July 8, 2026.